In a recent study, the antitumor effect of an oncolytic virus (Delta-24-ACT) armed with a 4-1BB ligand was evaluated alone and in combination with an immune checkpoint inhibitor (anti-PD-L1 antibody) in preclinical glioma models. Here, CD274 is linked to central nervous system cancer.